Your cart

×
Note: As of September 30th there will be order processing and shipment delays that may last until October 8, 2020 as we are transitioning to a new ERP system. Please email information@gyrosproteintech.com to discuss what accommodations we can provide during this time.

Peptide inhibitor of methylation casts new light on epigenetic-based cancer therapy

Jul 1, 2020 12:00:00 AM

The first peptide-derived epigenetic drug (Romidepsin) was approved in 2009 for the treatment of cutaneous T cell lymphomas (CTCL), and in 2011 for peripheral T cell lymphomas (PTCL) (2). Romidepsin also has potential in the treatment of other kinds of cancer, lung fibrosis, and Epstein-Barr infections. Currently, it is the only FDA-approved peptide medicine specifically designed to target epigenetic effects. Nesiritide, a peptide originally approved in 2001 for the symptomatic treatment of acute decompensated heart failure due to its vasodilating activity has since been repurposed due to its epigenetic effects. These peptides are not yet approved in the European Union by the EMA.

Read More

Topics: Prelude, Peptide synthesis, Protein-Protein Interactions (PPIs), Peptide synthesizer, Cyclic peptides